Cardiothoracic & vascular anaesthesia

Postoperative 20% Albumin Infusion and Acute Kidney Injury in High-Risk Cardiac Surgery Patients: The ALBICS Acute Kidney Injury (AKI) Randomized Clinical Trial

JAMA SurgPublished Randomised controlled trial

Authors' conclusion

In this study of cardiac surgery patients at high risk of AKI, an infusion of 20% albumin increased the risk of AKI.

Study context

Population
High-risk on-pump cardiac surgery patients (preoperative estimated glomerular filtration rate (eGFR) >15 and <60 mL/min/1.73 m², or combined cardiac procedure or major aortic surgery), 7 cardiac centres in Australia and Italy, 2019–2024primary analysis
Participants
307 vs 304
Comparison
Postoperative 20% albumin infusion vs usual care
  • 20% albuminn = 307
  • Usual caren = 304reference
Primary endpoint
Stage 1-3 AKI (creatinine-based Kidney Disease Improving Global Outcomes definition)
Methodological detailsinvestigator-initiated, multicentre, open-label, pragmatic, stratified by site and eGFR
  • Investigator-initiated
  • Multicentre
  • Open-label
  • Pragmatic
  • Stratified by site and eGFR

Primary result

As reported in the abstract

Each group vs usual careEstimate (95% CI)P value
20% albumin
unadjusted RR 1.13(0.95–1.34)
P = 0.18
20% albumin
strata-adjusted RR 1.12(1.04–1.21)
P = 0.003

Secondary outcomes

OutcomeAdjusted RR (95% CI)P value
AKI (subgroup eGFR <60 mL/min/1.73 m²)1.14 (1.07–1.22)P < 0.001

Other secondary outcomes (incl. major adverse kidney events, mortality)

No other significant differences in secondary outcomes

Safety

OutcomeP value
Blood transfusionsP = 0.04

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Postoperative 20% Albumin Infusion and Acute Kidney Injury in High-Risk Cardiac Surgery Patients: The ALBICS AKI Randomized Clinical Trial. JAMA Surg. Published 1 August 2025. doi:10.1001/jamasurg.2025.1683

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.